#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating pediatric drug-resistant epilepsy need to understand the access barriers their patients face, as NHS funding gaps for medical cannabis create a two-tiered system where only families with financial resources can obtain evidence-based treatment options. This campaign highlights a critical care gap that directly impacts clinical outcomes, since children who could benefit from cannabinoid therapy may go untreated due to cost and regulatory hurdles rather than medical unsuitability. Advocating for equitable NHS access to medical cannabis enables clinicians to offer their most vulnerable patients a potentially seizure-reducing therapy that current first-line medications have failed to control.
A campaign launched in the United Kingdom is advocating for improved NHS access to medical cannabis for pediatric patients with drug-resistant epilepsy, spurred by the case of a mother who played a pivotal role in changing UK medical cannabis legislation. Despite the legal framework permitting medical cannabis use, significant barriers to NHS provision remain, leaving families with children suffering from severe, refractory seizures unable to obtain cannabis-based treatments through standard healthcare channels. The campaign highlights a critical gap between policy reform and clinical implementation, where regulatory approval has not translated into equitable patient access or consistent prescribing pathways within the NHS system. This advocacy effort underscores the frustration of families who must either self-fund expensive private treatments, pursue legal challenges, or remain without access to a potentially beneficial therapeutic option. For clinicians, this represents an ongoing tension between evidence-based options and healthcare system constraints that may limit their ability to offer or discuss cannabis-based treatments with eligible pediatric patients. Physicians caring for children with refractory epilepsy should remain informed about evolving access mechanisms and consider engaging with patient advocacy efforts to understand real-world barriers their patients face in obtaining this medication.
“What we’re seeing with these access barriers is a clinical failure, not a scientific one—the evidence for cannabinoids in drug-resistant epilepsy is robust enough that we’re effectively condemning children to preventable seizures based on bureaucratic inertia rather than pharmacology, and that’s a decision we’ll have to answer for.”
💊 While the legalization of medical cannabis in the UK represented a significant policy shift for childhood drug-resistant epilepsy, translating this regulatory change into meaningful patient access remains challenging for clinicians and families navigating NHS provision. The evidence base for cannabis-derived treatments like cannabidiol in seizure reduction is genuine but modest, with responders representing a subset of eligible children and outcomes varying considerably based on individual seizure phenotypes and comorbidities. Systemic barriers including limited NHS commissioning, specialist prescriber availability, and ongoing uncertainty around optimal dosing and long-term safety complicate the clinical picture beyond the regulatory approval itself. Practitioners should maintain realistic conversations with families about efficacy expectations, acknowledge the genuine frustration when approved treatments remain inaccessible, and explore what comprehensive seizure management looks like whether or not cannabis-based therapy becomes available. Given these access disparities, clinicians have an advocacy role in documenting treatment failures and engaging with
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: